Business
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
SAN DIEGO, May 08, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results.
About this update from Revelation Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":780,"height":315,"url":"https://media.zenfs.com/en/business-wire.com/d90a4917bccbf0fede418a10a7aad00d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/R3w5fVFb2PApqbwC05bwvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d90a4917bccbf0fede418a10a7aad00d","width":780,"height":315},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lFRgzZZ1QrFJYbg8f6nYeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE1NjA7aD02MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d90a4917bccbf0fede418a10a7aad00d","width":780,"height":315}},"lazy":false},{"type":"text","content":"SAN DIEGO, May 08, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results.","length":313,"tagName":"p"},{"type":"text","content":"Corporate Highlights","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced a new indication for Gemini in severe burn patients","length":61,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells","length":98,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients","length":92,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":251,"olType":false},{"type":"text","content":""While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe burns," said James Rolke, Chief Executive Officer of Revelation. "We are also looking forward to the Phase 1b PRIME clinical study topline data this summer."","length":339,"tagName":"p"},{"type":"text","content":"Results of Operations","length":21,"tagName":"p"},{"type":"text","content":"As of March 31, 2025, Revelation had $3.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024. The decre...